Literature DB >> 8930999

Orphanin FQ is a functional anti-opioid peptide.

J S Mogil1, J E Grisel, R K Reinscheid, O Civelli, J K Belknap, D K Grandy.   

Abstract

The heptadecapeptide orphanin FQ has recently been shown to be the endogenous agonist for the orphan opioid-like receptor, LC132. The molecular evidence that LC132 and orphanin FQ are evolutionarily related to other opioid receptors and their ligands suggests that these proteins may also play a role in modulating opiate actions. We now report that orphanin FQ (0.5-10 nmol), injected intracerebroventricularly in mice, does not produce hyperalgesia as suggested previously but rather reverses opioid-mediated (i.e. naloxone-sensitive) stress-induced antinociception in three different algesiometric assays. In addition to its antagonism of endogenous opioid antinociception, orphanin FQ dose-dependently (2.5-25 nmol) reverses systemic morphine antinociception (5 mg/kg, s.c.). Based on these data, we propose that orphanin FQ is a functional anti-opioid peptide.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8930999     DOI: 10.1016/0306-4522(96)00338-7

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  65 in total

1.  Orphanin-FQ/nociceptin (OFQ/N) modulates the activity of suprachiasmatic nucleus neurons.

Authors:  C N Allen; Z G Jiang; K Teshima; T Darland; M Ikeda; C S Nelson; D I Quigley; T Yoshioka; R G Allen; M A Rea; D K Grandy
Journal:  J Neurosci       Date:  1999-03-15       Impact factor: 6.167

2.  A new synthesis of the ORL-1 antagonist 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidinyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one (J-113397) and activity in a calcium mobilization assay.

Authors:  Emilie D Smith; N Ariane Vinson; Desong Zhong; Bertold D Berrang; Jennifer L Catanzaro; James B Thomas; Hernán A Navarro; Brian P Gilmour; Jeffrey Deschamps; F Ivy Carroll
Journal:  Bioorg Med Chem       Date:  2007-10-13       Impact factor: 3.641

3.  Nociceptin/orphanin FQ blocks the antinociception induced by mu, kappa and delta opioid agonists on the cold water tail-flick test.

Authors:  Xiaohong Chen; Ellen B Geller; Martin W Adler
Journal:  Eur J Pharmacol       Date:  2006-11-10       Impact factor: 4.432

4.  Effects of nociceptin and nocistatin on antidromic vasodilatation in hairless skin of the rat hindlimb in vivo.

Authors:  H Häbler; L Timmermann; J Stegmann; W Jänig
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

5.  Brain and whole-body imaging in rhesus monkeys of 11C-NOP-1A, a promising PET radioligand for nociceptin/orphanin FQ peptide receptors.

Authors:  Yasuyuki Kimura; Masahiro Fujita; Jinsoo Hong; Talakad G Lohith; Robert L Gladding; Sami S Zoghbi; Johannes A Tauscher; Nancy Goebl; Karen S Rash; Zhaogen Chen; Concepcion Pedregal; Vanessa N Barth; Victor W Pike; Robert B Innis
Journal:  J Nucl Med       Date:  2011-08-30       Impact factor: 10.057

6.  Nociceptin Receptors Upregulated in Cocaine Use Disorder: A Positron Emission Tomography Imaging Study Using [11C]NOP-1A.

Authors:  Rajesh Narendran; Savannah Tollefson; Michael L Himes; Jennifer Paris; Brian Lopresti; Roberto Ciccocioppo; N Scott Mason
Journal:  Am J Psychiatry       Date:  2019-05-06       Impact factor: 18.112

7.  Comparison of the antinociceptive and antirewarding profiles of novel bifunctional nociceptin receptor/mu-opioid receptor ligands: implications for therapeutic applications.

Authors:  Lawrence Toll; Taline V Khroyan; Willma E Polgar; Faming Jiang; Cris Olsen; Nurulain T Zaveri
Journal:  J Pharmacol Exp Ther       Date:  2009-09-22       Impact factor: 4.030

8.  Buprenorphine: a unique drug with complex pharmacology.

Authors:  Kabirullah Lutfy; Alan Cowan
Journal:  Curr Neuropharmacol       Date:  2004-10       Impact factor: 7.363

Review 9.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Authors:  Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri
Journal:  Pharmacol Rev       Date:  2016-03-08       Impact factor: 25.468

10.  Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system.

Authors:  Roberto Ciccocioppo; Daina Economidou; Roberto Rimondini; Wolfgang Sommer; Maurizio Massi; Markus Heilig
Journal:  Biol Psychiatry       Date:  2006-03-14       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.